Advanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis

Conditions

Unknown Sites | Urinary Bladder

Phase COVID-NA

Volunteers
Health Professionals

What is the purpose of this trial?

We hypothesize that advanced CMR can detect myocardial structural, functional, and metabolic changes associated with autoimmune myocarditis in cardio-toxicity associated with CPI therapy of the PD-1 pathway in cancer patients. We propose to do this by applying advanced CMR methods for edema and fibrosis to detect early inflammation and cardio-toxicity in patients receiving CPI therapy.

Find out more about who can participate in this trial

Trial with
American Heart Association
Start Date
10/29/2018
End Date
09/30/2024

For more information about this study, contact:

Donna McMahon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Lauren A. Baldassarre, MD, FACC
Associate Professor of Medicine (Cardiovascular Medicine); Vice Chief, Cardiovascular Medicine, Faculty Life, Cardiovascular Medicine; Cardiology Director of Cardiac MR/CT, Advanced Cardiovascular CT/MR Program; Director, Cardio-Oncology, Cardiovascular Medicine; Director, Cardio-Oncology Advanced Training Fellowship Program, Cardiovascular Medicine; Vice Chief of Diversity, Equity and Inclusion, Cardiovascular Medicine

Sub-Investigators

Last Updated
12/22/2022
Study HIC
#2000023943

Advanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information